Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Core Viewpoint - Phathom Pharmaceuticals reported a quarterly loss of $1.07 per share, slightly worse than the consensus estimate of a loss of $1.06, but an improvement from a loss of $1.42 per share a year ago [1] Financial Performance - The company posted revenues of $28.52 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 1.06% and significantly up from $1.91 million in the same quarter last year [2] - Over the last four quarters, Phathom Pharmaceuticals has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - Phathom Pharmaceuticals shares have declined approximately 47.2% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.97 on revenues of $38.23 million, and for the current fiscal year, it is -$3.55 on revenues of $167.86 million [7] Earnings Outlook - The estimate revisions trend for Phathom Pharmaceuticals is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Phathom Pharmaceuticals belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8]